Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

How to promote and hardwire bedside patient handoff.

Waters VL.

Nurs Manage. 2019 Aug;50(8):7-9. doi: 10.1097/01.NUMA.0000575340.23948.51. No abstract available.

PMID:
31361690
2.

Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections.

Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Gilligan P; Antimicrobial Resistance International Working Group in Cystic Fibrosis.

Clin Infect Dis. 2019 May 6. pii: ciz364. doi: 10.1093/cid/ciz364. [Epub ahead of print]

PMID:
31056660
3.

The culture, mental health and psychosocial wellbeing of Rohingya refugees: a systematic review.

Tay AK, Riley A, Islam R, Welton-Mitchell C, Duchesne B, Waters V, Varner A, Moussa B, Mahmudul Alam ANM, Elshazly MA, Silove D, Ventevogel P.

Epidemiol Psychiatr Sci. 2019 Oct;28(5):489-494. doi: 10.1017/S2045796019000192. Epub 2019 Apr 22.

PMID:
31006421
4.

Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.

Klingel M, Stanojevic S, Tullis E, Ratjen F, Waters V.

Ann Am Thorac Soc. 2019 Jul;16(7):861-867. doi: 10.1513/AnnalsATS.201811-774OC.

PMID:
30874447
5.

Disseminating Information on Evidence-Based Practices for Children and Youth with Autism Spectrum Disorder: AFIRM.

Sam AM, Cox AW, Savage MN, Waters V, Odom SL.

J Autism Dev Disord. 2019 Feb 28. doi: 10.1007/s10803-019-03945-x. [Epub ahead of print]

PMID:
30820727
6.

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review.

Somayaji R, Parkins MD, Shah A, Martiniano SL, Tunney MM, Kahle JS, Waters VJ, Elborn JS, Bell SC, Flume PA, VanDevanter DR; Antimicrobial Resistance in Cystic Fibrosis InternationalWorking Group.

J Cyst Fibros. 2019 Mar;18(2):236-243. doi: 10.1016/j.jcf.2019.01.008. Epub 2019 Jan 30.

PMID:
30709744
7.

Microbiome networks and change-point analysis reveal key community changes associated with cystic fibrosis pulmonary exacerbations.

Layeghifard M, Li H, Wang PW, Donaldson SL, Coburn B, Clark ST, Caballero JD, Zhang Y, Tullis DE, Yau YCW, Waters V, Hwang DM, Guttman DS.

NPJ Biofilms Microbiomes. 2019 Jan 21;5:4. doi: 10.1038/s41522-018-0077-y. eCollection 2019.

8.

Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams.

Clark ST, Sinha U, Zhang Y, Wang PW, Donaldson SL, Coburn B, Waters VJ, Yau YCW, Tullis DE, Guttman DS, Hwang DM.

Int J Antimicrob Agents. 2019 May;53(5):620-628. doi: 10.1016/j.ijantimicag.2019.01.009. Epub 2019 Jan 19.

PMID:
30664925
9.

A genome-wide association analysis reveals a potential role for recombination in the evolution of antimicrobial resistance in Burkholderia multivorans.

Diaz Caballero J, Clark ST, Wang PW, Donaldson SL, Coburn B, Tullis DE, Yau YCW, Waters VJ, Hwang DM, Guttman DS.

PLoS Pathog. 2018 Dec 7;14(12):e1007453. doi: 10.1371/journal.ppat.1007453. eCollection 2018 Dec.

10.

Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms.

Beaudoin T, Stone TA, Glibowicka M, Adams C, Yau Y, Ahmadi S, Bear CE, Grasemann H, Waters V, Deber CM.

Sci Rep. 2018 Oct 3;8(1):14728. doi: 10.1038/s41598-018-33016-7.

11.

Antimicrobial resistance in cystic fibrosis: Does it matter?

Flume PA, Waters VJ, Bell SC, Van Devanter DR, Stuart Elborn J; Antimicrobial Resistance in Cystic Fibrosis International Working Group.

J Cyst Fibros. 2018 Nov;17(6):687-689. doi: 10.1016/j.jcf.2018.08.015. Epub 2018 Sep 27. No abstract available.

PMID:
30270113
12.

Defining antimicrobial resistance in cystic fibrosis.

Kidd TJ, Canton R, Ekkelenkamp M, Johansen HK, Gilligan P, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Waters VJ; Antimicrobial Resistance in Cystic Fibrosis International Working Group.

J Cyst Fibros. 2018 Nov;17(6):696-704. doi: 10.1016/j.jcf.2018.08.014. Epub 2018 Sep 25. Review.

PMID:
30266518
13.

Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Parkins MD, Somayaji R, Waters VJ.

Clin Microbiol Rev. 2018 Aug 29;31(4). pii: e00019-18. doi: 10.1128/CMR.00019-18. Print 2018 Oct. Review.

14.

Prevalence of tuberculosis infection and disease in children referred for tuberculosis medical surveillance in Ontario: a single-cohort study.

Yang C, Yasseen AS 3rd, Stimec J, Rea E, Waters V, Lam R, Morris SK, Kitai I.

CMAJ Open. 2018 Aug 28;6(3):E365-E371. doi: 10.9778/cmajo.20180043. Print 2018 Jul-Sep.

15.

Burkholderia multivorans septicemia in a pediatric liver transplant patient.

Ho SSC, Nashid N, Waters VJ, LiPuma JJ, Zlosnik JEA, Otley A, Somers GR, Kamath BM, Yau YCW.

Am J Transplant. 2019 Mar;19(3):933-938. doi: 10.1111/ajt.15065. Epub 2018 Sep 5.

PMID:
30091842
16.

Epidemiology of Clonal Pseudomonas aeruginosa Infection in a Canadian Cystic Fibrosis Population.

Middleton MA, Layeghifard M, Klingel M, Stanojevic S, Yau YCW, Zlosnik JEA, Coriati A, Ratjen FA, Tullis ED, Stephenson A, Wilcox P, Freitag A, Chilvers M, McKinney M, Lavoie A, Wang PW, Guttman DS, Waters VJ.

Ann Am Thorac Soc. 2018 Jul;15(7):827-836. doi: 10.1513/AnnalsATS.201801-007OC.

PMID:
29911888
17.

Chronic Antibiotic Use in Cystic Fibrosis: A Fine Balance.

Waters V.

Ann Am Thorac Soc. 2018 Jun;15(6):667-668. doi: 10.1513/AnnalsATS.201803-172ED. No abstract available.

PMID:
29856253
18.

Defining chronic Pseudomonas aeruginosa infection in cystic fibrosis.

Waters V, Grimwood K.

J Cyst Fibros. 2018 May;17(3):292-293. doi: 10.1016/j.jcf.2018.03.007. Epub 2018 Mar 27. No abstract available.

PMID:
29602718
19.

Isolated cutaneous mucormycosis in a pediatric renal transplant recipient.

Downie ML, Alghounaim M, Davidge KM, Yau Y, Walsh TJ, Pope E, Somers GR, Waters V, Robinson LA.

Pediatr Transplant. 2018 Jun;22(4):e13172. doi: 10.1111/petr.13172. Epub 2018 Mar 23.

PMID:
29569805
20.

Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment.

Blanchard AC, Rooney AM, Yau Y, Zhang Y, Stapleton PJ, Horton E, Klingel M, Stanojevic S, Ratjen F, Coburn B, Waters V.

J Cyst Fibros. 2018 Nov;17(6):723-728. doi: 10.1016/j.jcf.2018.02.008. Epub 2018 Mar 7.

PMID:
29525410
21.

Identification of the Receptor and Cellular Ortholog of the Marek's Disease Virus (MDV) CXC Chemokine.

Haertle S, Alzuheir I, Busalt F, Waters V, Kaiser P, Kaufer BB.

Front Microbiol. 2017 Dec 15;8:2543. doi: 10.3389/fmicb.2017.02543. eCollection 2017.

22.

What Do Faculty in Health Professions Need to be Competent Educators? Results from a School-Wide Needs Assessment.

Gardner AK, Waters V, McLaughlin RJ.

J Allied Health. 2017 Winter;46(4):e77-e80.

PMID:
29202168
23.

Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance.

Beaudoin T, Yau YCW, Stapleton PJ, Gong Y, Wang PW, Guttman DS, Waters V.

NPJ Biofilms Microbiomes. 2017 Oct 19;3:25. doi: 10.1038/s41522-017-0035-0. eCollection 2017.

24.

Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.

Waters V, Ratjen F.

Cochrane Database Syst Rev. 2017 Oct 5;10:CD009528. doi: 10.1002/14651858.CD009528.pub4. Review.

25.

MexXY efflux pump overexpression and aminoglycoside resistance in cystic fibrosis isolates of Pseudomonas aeruginosa from chronic infections.

Singh M, Yau YCW, Wang S, Waters V, Kumar A.

Can J Microbiol. 2017 Dec;63(12):929-938. doi: 10.1139/cjm-2017-0380. Epub 2017 Sep 18.

PMID:
28922614
26.

Optimizing Blood Collection and Processing for Quantiferon-TB Gold in-Tube Testing Gives Low Rates of Indeterminate Results: Clinical Implications.

Kordy F, Waters V, Den-Hollander C, Read S, Lam R, Kitai I.

Pediatr Infect Dis J. 2018 Jan;37(1):e22-e24. doi: 10.1097/INF.0000000000001732.

PMID:
28787385
27.

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.

Waters V, Ratjen F.

Cochrane Database Syst Rev. 2017 Jun 19;6:CD006961. doi: 10.1002/14651858.CD006961.pub4. Review.

28.

Clinical Outcomes Associated with Achromobacter Species Infection in Patients with Cystic Fibrosis.

Somayaji R, Stanojevic S, Tullis DE, Stephenson AL, Ratjen F, Waters V.

Ann Am Thorac Soc. 2017 Sep;14(9):1412-1418. doi: 10.1513/AnnalsATS.201701-071OC.

PMID:
28406714
29.

Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection.

Waters V, Yau Y, Beaudoin T, Wettlaufer J, Tom SK, McDonald N, Rizvi L, Klingel M, Ratjen F, Tullis E.

J Cyst Fibros. 2017 Jul;16(4):492-495. doi: 10.1016/j.jcf.2017.02.008. Epub 2017 Mar 3.

30.

Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis.

Blanchard AC, Horton E, Stanojevic S, Taylor L, Waters V, Ratjen F.

J Cyst Fibros. 2017 May;16(3):395-400. doi: 10.1016/j.jcf.2017.01.007. Epub 2017 Feb 9.

31.

Navigating social and ethical challenges of biobanking for human microbiome research.

Chuong KH, Hwang DM, Tullis DE, Waters VJ, Yau YC, Guttman DS, O'Doherty KC.

BMC Med Ethics. 2017 Jan 11;18(1):1. doi: 10.1186/s12910-016-0160-y.

32.

Visualizing the Effects of Sputum on Biofilm Development Using a Chambered Coverglass Model.

Beaudoin T, Kennedy S, Yau Y, Waters V.

J Vis Exp. 2016 Dec 14;(118). doi: 10.3791/54819.

33.

5 SOFT SKILLS FOR PHYSICIAN LEADERS.

Waters V.

Physician Leadersh J. 2017 Jan;4(1):36-38.

PMID:
30571893
34.

Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.

Waters V, Ratjen F.

Cochrane Database Syst Rev. 2016 Dec 19;12:CD010004. doi: 10.1002/14651858.CD010004.pub4. Review.

35.

Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis.

Waters V, Stanojevic S, Ratjen F.

Expert Rev Respir Med. 2016 Nov;10(11):1221-1228. doi: 10.1080/17476348.2017.1246963. Epub 2016 Oct 20.

PMID:
27718754
36.

Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis.

Stanojevic S, McDonald A, Waters V, MacDonald S, Horton E, Tullis E, Ratjen F.

Thorax. 2017 Apr;72(4):327-332. doi: 10.1136/thoraxjnl-2016-208450. Epub 2016 Aug 18.

PMID:
27539619
37.

Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Amin R, Waters V.

Cochrane Database Syst Rev. 2016 Jul 14;7:CD009249. doi: 10.1002/14651858.CD009249.pub4. Review.

38.

Longitudinal study of Stenotrophomonas maltophilia antibody levels and outcomes in cystic fibrosis patients.

Wettlaufer J, Klingel M, Yau Y, Stanojevic S, Tullis E, Ratjen F, Waters V.

J Cyst Fibros. 2017 Jan;16(1):58-63. doi: 10.1016/j.jcf.2016.06.007. Epub 2016 Jun 23.

39.

Heuristic decision-making about research participation in children with cystic fibrosis.

Christofides E, Dobson JA, Solomon M, Waters V, O'Doherty KC.

Soc Sci Med. 2016 Aug;162:32-40. doi: 10.1016/j.socscimed.2016.06.017. Epub 2016 Jun 13.

PMID:
27328055
40.

Infections With Biofilm Formation: Selection of Antimicrobials and Role of Prolonged Antibiotic Therapy.

Beaudoin T, Waters V.

Pediatr Infect Dis J. 2016 Jun;35(6):695-7. doi: 10.1097/INF.0000000000001144. Review. No abstract available.

PMID:
26986772
41.

Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient.

Balwan A, Nicolau DP, Wungwattana M, Zuckerman JB, Waters V.

Antimicrob Agents Chemother. 2015 Dec 31;60(1):1-5. doi: 10.1128/AAC.01428-15. Print 2016 Jan.

42.

Pulmonary Exacerbations in Children with Cystic Fibrosis.

Waters V, Ratjen F.

Ann Am Thorac Soc. 2015 Nov;12 Suppl 2:S200-6. doi: 10.1513/AnnalsATS.201502-098AW. Review.

PMID:
26595740
43.

Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia.

Ratjen F, Waters V, Klingel M, McDonald N, Dell S, Leahy TR, Yau Y, Grasemann H.

Eur Respir J. 2016 Mar;47(3):829-36. doi: 10.1183/13993003.01390-2015. Epub 2015 Nov 19.

44.

Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients.

Tom SK, Yau YC, Beaudoin T, LiPuma JJ, Waters V.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):650-2. doi: 10.1128/AAC.02240-15. Print 2016 Jan.

45.

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.

Waters V, Ratjen F.

Cochrane Database Syst Rev. 2015 Nov 2;(11):CD006961. doi: 10.1002/14651858.CD006961.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 Jun 19;6:CD006961.

PMID:
26522473
46.

Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms.

Kennedy S, Beaudoin T, Yau YC, Caraher E, Zlosnik JE, Speert DP, LiPuma JJ, Tullis E, Waters V.

Antimicrob Agents Chemother. 2015 Oct 26;60(1):348-55. doi: 10.1128/AAC.02068-15. Print 2016 Jan.

47.

Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis.

Vidya P, Smith L, Beaudoin T, Yau YC, Clark S, Coburn B, Guttman DS, Hwang DM, Waters V.

Eur J Clin Microbiol Infect Dis. 2016 Jan;35(1):67-74.

PMID:
26492874
48.

An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis.

Geake JB, Reid DW, Currie BJ, Bell SC; MelioidCF Investigators, Bright-Thomas R, Dewar J, Holden S, Simmonds N, Gyi K, Kenna D, Waters V, Jackson M, O'Sullivan B, Taccetti G, Kolbe J, O'Carroll M, Campbell D, Jaksic M, Radhakrishna N, Kidd TJ, Flight W.

BMC Pulm Med. 2015 Oct 9;15:116. doi: 10.1186/s12890-015-0109-9.

49.

Selective Sweeps and Parallel Pathoadaptation Drive Pseudomonas aeruginosa Evolution in the Cystic Fibrosis Lung.

Diaz Caballero J, Clark ST, Coburn B, Zhang Y, Wang PW, Donaldson SL, Tullis DE, Yau YC, Waters VJ, Hwang DM, Guttman DS.

MBio. 2015 Sep 1;6(5):e00981-15. doi: 10.1128/mBio.00981-15.

50.

Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations.

Waters V, Stanojevic S, Klingel M, Chiang J, Sonneveld N, Kukkar R, Tullis E, Ratjen F.

J Cyst Fibros. 2015 Nov;14(6):770-6. doi: 10.1016/j.jcf.2015.07.010. Epub 2015 Aug 9.

Supplemental Content

Loading ...
Support Center